Literature DB >> 12384178

Neuropeptide Y (NPY) and depression: from animal studies to the human condition.

John P Redrobe1, Yvan Dumont, Rémi Quirion.   

Abstract

Neuropeptide Y (NPY) is widely distributed throughout the central nervous system (CNS) and is one of the most conserved peptides in evolution, suggesting an important role in the regulation of basic physiological functions. In addition, both pre-clinical and clinical evidence have suggested that NPY, together with its receptors, may have a direct implication in several psychiatric disorders, including depression and related illnesses. NPY-like immunoreactivity and NPY receptors are expressed throughout the brain, with varying concentrations being found throughout the limbic system. Such brain structures have been repeatedly implicated in the modulation of emotional processing, as well as in the pathogenesis of depressive disorders. This review will concentrate on the distribution of NPY, its receptors, and the putative role played by this peptide in depressive illness based on both pre-clinical and clinical evidence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384178     DOI: 10.1016/s0024-3205(02)02159-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  30 in total

1.  Effects of prolonged ethanol vapor exposure on forced swim behavior, and neuropeptide Y and corticotropin-releasing factor levels in rat brains.

Authors:  Brendan M Walker; David A Drimmer; Jennifer L Walker; Tianmin Liu; Aleksander A Mathé; Cindy L Ehlers
Journal:  Alcohol       Date:  2010-08-12       Impact factor: 2.405

2.  BODIPY-conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes.

Authors:  Yvan Dumont; Pierrette Gaudreau; Manuela Mazzuferi; Daniel Langlois; Jean-Guy Chabot; Alain Fournier; Michele Simonato; Rémi Quirion
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

3.  Effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats.

Authors:  Daria Rylkova; Jeffrey Boissoneault; Shani Isaac; Melissa Prado; Hina P Shah; Adrie W Bruijnzeel
Journal:  Neuropeptides       Date:  2008-05-12       Impact factor: 3.286

4.  Sexual deprivation increases ethanol intake in Drosophila.

Authors:  G Shohat-Ophir; K R Kaun; R Azanchi; H Mohammed; U Heberlein
Journal:  Science       Date:  2012-03-16       Impact factor: 47.728

5.  A rodent model of traumatic stress induces lasting sleep and quantitative electroencephalographic disturbances.

Authors:  Michael T Nedelcovych; Robert W Gould; Xiaoyan Zhan; Michael Bubser; Xuewen Gong; Michael Grannan; Analisa T Thompson; Magnus Ivarsson; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones
Journal:  ACS Chem Neurosci       Date:  2015-01-28       Impact factor: 4.418

6.  Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater bone mineral density.

Authors:  K L Seldeen; P G Halley; C H Volmar; M A Rodríguez; M Hernandez; M Pang; S K Carlsson; L J Suva; C Wahlestedt; B R Troen; S P Brothers
Journal:  Neuropeptides       Date:  2017-11-07       Impact factor: 3.286

7.  The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus.

Authors:  Smita Thakker-Varia; Jennifer Jernstedt Krol; Jacob Nettleton; Parizad M Bilimoria; Debra A Bangasser; Tracey J Shors; Ira B Black; Janet Alder
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

Review 8.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

9.  The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice.

Authors:  Rose-Marie Karlsson; Jessica S Choe; Heather A Cameron; Annika Thorsell; Jacqueline N Crawley; Andrew Holmes; Markus Heilig
Journal:  Psychopharmacology (Berl)       Date:  2007-09-22       Impact factor: 4.530

10.  Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125I][hPP1-17, Ala31, Aib32]NPY.

Authors:  Yvan Dumont; Mira Thakur; Annette Beck-Sickinger; Alain Fournier; Rémi Quirion
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.